Aortic Arch Calcification and the Risk of Cancer: A Population-Based Cohort Study

Janine E. van der Toorn1,2†, Kimberly D. van der Willik1,3†, Rikje Ruiter1, Meike W. Vernooij1,2, Bruno H.Ch. Stricker1, Sanne B. Schagen3,4, M. Arfan Ikram1, Maryam Kavousi1 and Daniel Bos1,2,5*

1Department of Epidemiology, Erasmus MC - University Medical Center, Rotterdam, Netherlands, 2Department of Radiology and Nuclear Medicine, Erasmus MC - University Medical Center, Rotterdam, Netherlands, 3Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands, 4Brain and Cognition, Department of Psychology, University of Amsterdam, Amsterdam, Netherlands, 5Department of Clinical Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States

Background: Atherosclerosis and cancer share multiple disease pathways. Yet, it is unclear if atherosclerosis is associated with a subsequent higher cancer risk. We determined the association of atherosclerotic calcification in the aortic arch, as proxy for systemic atherosclerosis, with the risk of cancer.

Methods: Between 2003 and 2006, 2,404 participants (mean age: 69.5 years, 52.5% women) from the prospective population-based Rotterdam Study underwent computed tomography to quantify calcification in the aortic arch. Participants were followed for the onset of cancer, death, loss to follow-up, or January 1st, 2015, whichever came first. We computed sex-specific tertiles of aortic arch calcification volumes. Next, we examined the association between the volume and severity (i.e., tertiles) of aortic arch calcification and the risk of cancer using Cox proportional hazard models.

Results: During a median (interquartile range) follow-up of 9.6 years (8.9–10.5), 348 participants were diagnosed with cancer. Participants with the greatest severity of aortic arch calcification had a higher risk of cancer [hazard ratio for the third tertile compared to the first tertile of aortic arch calcification volume in the total population is 1.39 (95% CI = 1.04–1.86)].

Conclusions: Individuals with the most severe aortic arch calcification had a higher risk of cancer. While this could reflect the impact of long-term exposure to shared risk factors, it might also point toward the co-occurrence of both conditions.

Keywords: atherosclerosis, calcification, cancer, cohort study, survival

INTRODUCTION

Cardiovascular diseases and cancer remain the leading causes of morbidity and mortality worldwide (1, 2). Several studies have shown that patients with cancer are at higher risk of developing cardiovascular disease (3, 4). This may be due to a cancer-induced hypercoagulable state (5), or as a consequence of the detrimental effects of cancer treatment on the vascular system (4, 6, 7). Additionally, it has also been proposed that atherosclerosis, the most important underlying condition of cardiovascular events, and cancer may share a common pathophysiology (8).
Common risk factors such as age, smoking, obesity, and genetic susceptibility are known to contribute to the risk of both atherosclerosis and cancer. Specific molecular pathways leading to atherosclerosis, including inflammation, oxidative stress, and uncontrolled cell proliferation, are also involved in the pathogenesis of cancer (9, 10). As such, both diseases are likely to co-occur. Although many studies have focused on the presence of atherosclerosis after cancer diagnosis, less is known about the presence and extent of atherosclerosis before cancer manifestation. This is of particular interest, since the first atherosclerotic lesions may already develop during infancy (11). Understanding the sequence and timing between these potentially interconnected diseases is pivotal as it may help to identify high-risk patients and to develop preventive strategies for both diseases.

Due to the central anatomical location in the arterial system, the presence and amount of atherosclerosis in the aortic arch may provide an easy measurable proxy of the systemic burden of atherosclerosis within an individual. As such, aortic arch atherosclerosis has repeatedly been linked to mortality, in particular also of non-cardiovascular origin, of which cancer represents a substantial part (12, 13). Hence, to further investigate the link between atherosclerosis and cancer, we determined the association between aortic arch calcification— as proxy for systemic atherosclerosis—with the subsequent risk of cancer within the setting of a large prospective population-based study.

METHOD

Setting
This study is embedded within the Rotterdam Study, a prospective population-based cohort study that investigates determinants and occurrence of chronic diseases in the middle-aged and elderly population. The design of the Rotterdam Study has been described in detail previously (14). At study entry, all participants were interviewed at home by a trained research assistant, followed by two visits to the research facility to undergo different examinations including laboratory assessments and imaging. Follow-up examinations take place every 3 to 5 years.

Study Population
For the present study, we used the follow-up visit between 2003 and 2006 as baseline, because during this period, participants who visited the research center were invited to undergo non-contrast multi-detector computed tomography (MDCT) scanning of the aortic arch as part of a project of visualizing arterial calcification (15). We scanned 2,524 participants (response rate, 78%). Out of 2,524 scans, 6 scans were ungradable for aortic arch calcification because of the presence of image artifacts, leaving a total of 2,518 complete examinations with information on calcification. We excluded participants with a history of cancer (n = 114), resulting in 2,404 participants for analysis. The follow-up for cancer took place continuously and was completed for this study until January 1st, 2015.

The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; www.trialregister.nl) and into the WHO International Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/network/primary/en/) under shared catalog number NTR6831. All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians.

Assessment of Aortic Arch Calcification
We used a 16-slice or 64-slice MDCT scanner (Somatom Sensation 16 or 64; Siemens, Forchheim, Germany) to perform non-contrast CT scanning. We scanned the aortic arch using an extra-cardiac scan that reached from the aortic arch to the intracranial vasculature (1 cm above the sella turcica). Detailed information on both scans is provided elsewhere (16, 17). As proxy of aortic arch atherosclerosis, we quantified aortic arch calcification on the extra-cardiac scan by including all calcification from the origin of the aortic arch (defined as the image in which the ascending and descending aorta merge into the inner curvature of the aortic arch) to the first 1 cm of the branches originating from the arch (18). Calcification volumes were calculated using dedicated software (Syngo Calcium Scoring; Siemens, Forchheim, Germany) and expressed in mm³.

Assessment of Cancer
Diagnoses of cancer were based on medical records of general practitioners (including hospital discharge letters) and through linkage with Dutch Hospital Data, the Netherlands Cancer Registry, and histology and cytopathology registries in the region. Incident cancer was defined as any primary malignant tumor, excluding non-melanoma skin cancer. Only pathology-confirmed cancers were included in analysis to exclude the possibility of false-positive cancer diagnoses. Diagnoses were coded independently by two physicians according to the International Classification of Diseases, Tenth Revision (ICD-10). In case of discrepancy, consensus was sought through consultation with a physician specialized in internal medicine. Date of diagnosis was based on date of biopsy (solid tumors) and laboratory assessment (hematologic tumors), or—if unavailable—date of hospital admission or discharge letter. Follow-up of cancer registration was complete until January 1st, 2015.

Measurement of Covariables
Information on educational level, smoking behavior, and use of antidiabetic, antihypertensive, lipid-lowering, and antithrombotic medication was obtained by trained interviewers. Educational level was classified into primary education, lower education (lower/intermediate general education or lower vocational education), intermediate education (intermediate vocational education or higher general education), or higher education (higher vocational education or university). Smoking
status was categorized as never, current, or former. At the research center, height and weight were measured from which the body mass index (BMI; kg/m²) was computed. Furthermore, systolic and diastolic blood pressures were measured twice on the right arm with a random-zero sphygmomanometer of which the mean was used for analyses. Hypertension was defined as a systolic blood pressure of ≥140 mm Hg, a diastolic blood pressure of ≥90 mm Hg, or use of antihypertensive medication (19). Hypercholesterolemia was defined as use of lipid-lowering medication or serum total cholesterol >6.5 mmol/L. Diabetes mellitus was defined as use of antidiabetic medication, fasting serum glucose level ≥7.1 mmol/L, or random serum glucose level ≥11.1 mmol/L (20). We defined history of cardiovascular disease as history of myocardial infarction, stroke, percutaneous transluminal coronary angioplasty, and/or coronary artery bypass graft (21–23). Granulocyte count was measured using the COULTER® Ac-T diff® Hematology Analyzer (Beckman Coulter, San Diego, California, USA).

Statistical Analysis
Considering the skewed distribution of aortic arch calcification volumes, we performed a natural log-transformation and added 1 mm³ to each non-transformed volume to deal with calcium scores of 0 (Ln[calcification volume + 1.00 mm³³]). First, we used Cox proportional hazard models to determine the association between aortic arch calcification [per 1-standard deviation (SD) increase] and the subsequent risk of cancer. Model 1 was adjusted for age at MDCT scan and sex. To investigate to which extent any association would be driven by shared risk factors, model 2 was additionally adjusted for shared risk factors including educational level, smoking status, BMI, hypertension (24), hypercholesterolemia (25), diabetes mellitus, history of cardiovascular disease, and granulocyte count. We chose to use granulocyte count as markers of inflammation, since these blood cells in particular are related to larger volumes of arterial calcification (26).

Second, we computed tertiles of calcification severity and investigated associations with the risk of cancer, using the same two Cox proportional hazard models as described above and using the first tertile as reference category. As calcification volumes were larger in men than in women, the tertiles were computed sex-specifically. Also, considering differences in risk factors for atherosclerosis and cancer between men and women (27), we performed analyses stratified by sex.

For all Cox proportional hazard models, follow-up time was used as timescale and started at date of MDCT scan until date of incident cancer, death, loss to follow-up, or January 1st, 2015, whichever came first. Censoring participants at date of death allowed us to compute cause-specific hazard ratios (HRs). The proportional hazards assumption was met for all analyses (Schoenfeld residuals test, all P > 0.05).

To explore the robustness of our findings, we performed several sensitivity analyses to assess potential bias associated with mortality given the strong association between atherosclerosis and mortality (13). First, we restricted the analyses to shorter follow-up periods to limit the number of mortality events. To this end, participants with longer follow-up duration were censored at, respectively, 2, 3, 4, and 5 years after the MDCT scan. Second, we repeated the continuous analyses for the most common cancer types, i.e., breast cancer (among women), prostate cancer (among men), colorectal cancer, and lung cancer. Third, we stratified analyses by use of lipid-lowering and antithrombotic medication, and by median granulocyte count. In addition, we formally tested interaction by adding multiplicative interaction terms to the model.

To account for missing data of covariables (maximum amount of missing data: 5.9%), we used multiple imputation (n = five imputations) by chained equations along with age, sex, calcification volumes, cardiovascular risk factors, and cancer incidence. Statistical analyses were performed using STATA v.15 (StataCorp).

RESULTS
Characteristics of participants at time of MDCT scan are presented in Table 1. In addition, population characteristics stratified by tertiles of aortic arch calcification volumes are shown in Supplementary Table 1. The mean (SD) age was 69.5 years (6.8), and 52.5% were women. Among participants in the highest tertile of aortic arch calcification, a higher prevalence of cardiovascular risk factors was observed than in participants in the lowest tertile. During a median (interquartile range) follow-up of 9.6 years (8.9–10.5), 348 out of 2,404 participants were diagnosed with cancer, and 463 participants died. The most frequently diagnosed cancer types were prostate (39.2% among men), breast (34.4% among women), colorectal (16.1% overall), and lung (11.5% overall).

We found no statistically significant association between continuous volumes of aortic arch calcification and the risk of cancer (Table 2). When investigating tertiles of calcification, we found that severe calcification was associated with a higher risk of cancer in the total population and in men (adjusted HR for the third tertile compared to the first tertile of aortic arch calcification in total population = 1.39, 95% CI = 1.04–1.86 and in men = 1.44, 95% CI = 1.00–2.09). This association was also observed in women, albeit not statistically significant (HR = 1.33, 95% CI = 0.83–2.13). Effect estimates were slightly attenuated when we corrected for different cardiovascular risk factors.

When censoring participants with a follow-up duration longer than 2 years, we found that effect estimates were higher for both continuous aortic arch calcification volume as well as for severe calcification, albeit not statistically significant (adjusted HR per 1-SD increase in aortic arch calcification = 1.24, 95% CI = 0.90–1.71, and adjusted HR for the third tertile compared to the first tertile of aortic arch calcification = 1.53, 95% CI = 0.75–2.13). The effect estimates decreased with inclusion of longer follow-up duration (Table 3).

Regarding specific cancer types, we found that among women, aortic arch calcification was associated with a lower risk of breast cancer (HR per 1-SD increase in aortic arch calcification = 0.71, 95% CI = 0.52–0.98) and with a higher risk of lung cancer in the total population (HR = 2.35, 95% CI = 1.39–3.96, Table 4).
Characteristics of the study population.

| Characteristic                      | All participants | Men          | Women         |
|-------------------------------------|------------------|--------------|--------------|
|                                     | (N = 2,404)      | (N = 1,143)  | (N = 1,261)  |
| Age*                                | 69.5 (6.8)       | 69.6 (6.6)   | 69.5 (6.9)   |
| Educational level                   |                  |              |              |
| Primary                             | 198 (8.2)        | 70 (6.1)     | 128 (10.2)   |
| Lower                               | 1023 (42.6)      | 298 (26.1)   | 725 (57.5)   |
| Intermediate                        | 737 (30.7)       | 444 (38.8)   | 293 (23.2)   |
| Higher                              | 446 (18.8)       | 331 (29.0)   | 115 (9.1)    |
| Body mass index*                    | 27.7 kg/m² (4.1) | 27.4 kg/m² (3.5) | 27.9 kg/m² (4.5) |
| Smoking                             |                  |              |              |
| Never                               | 687 (28.8)       | 157 (13.7)   | 530 (42.0)   |
| Former                              | 1339 (55.7)      | 777 (68.0)   | 562 (44.6)   |
| Current                             | 378 (15.7)       | 209 (18.3)   | 169 (13.4)   |
| Hypertension                        |                  |              |              |
| No                                  | 604 (25.1)       | 283 (24.8)   | 321 (25.5)   |
| Yes                                 | 1800 (74.9)      | 860 (75.2)   | 940 (74.5)   |
| Hypercholesterolemia                |                  |              |              |
| No                                  | 1387 (57.7)      | 721 (63.1)   | 666 (52.8)   |
| Yes                                 | 1017 (42.3)      | 422 (36.9)   | 595 (47.2)   |
| Lipid-lowering medication use       |                  |              |              |
| No                                  | 1806 (75.1)      | 851 (74.5)   | 955 (75.7)   |
| Yes                                 | 598 (24.9)       | 292 (25.5)   | 306 (24.3)   |
| Antithrombotic medication use       |                  |              |              |
| No                                  | 1813 (75.4)      | 794 (69.5)   | 1019 (80.8)  |
| Yes                                 | 591 (24.6)       | 349 (30.5)   | 242 (19.2)   |
| Diabetes mellitus                   |                  |              |              |
| No                                  | 2076 (86.4)      | 973 (85.1)   | 1103 (87.5)  |
| Yes                                 | 328 (13.6)       | 170 (14.9)   | 158 (12.5)   |
| History of cardiovascular disease   |                  |              |              |
| No                                  | 2108 (87.7)      | 939 (82.2)   | 1169 (92.7)  |
| Yes                                 | 296 (12.3)       | 204 (17.8)   | 92 (7.3)     |
| Granulocyte count†                  | 3.8 (3.0–4.6)    | 4.0 (3.2–4.8) | 3.6 (2.9–4.4) |
| Aortic arch calcification†          | 263.8 mm³ (46.5–883.2) | 296.9 mm³ (52.9–1009.5) | 228.5 mm³ (41.8–825.0) |

Characteristics are measured at time of MDCT scan. Data are presented as frequency (percent) unless indicated otherwise. Numbers are shown after multiple imputation. *Presented as mean (standard deviation). †Presented as median (interquartile range).

No effect modification was observed by lipid-lowering and antithrombotic medication use and by median granulocyte count. All interactions were tested on the multiplicative scale and did not reach statistical significance (P > 0.05).

DISCUSSION

In this population-based study, we found that only individuals with the most severe aortic arch calcification had a higher risk of cancer, in particular in the short term.

It has previously been shown that atherosclerosis and cardiovascular events occur after cancer diagnosis potentially as a result of cancer itself—by inducing a hypercoagulable state—and cancer treatment. Based on the shared risk factors and pathophysiology, we hypothesized that atherosclerosis is also associated with a subsequent higher risk of cancer and that the strength of this association would diminish after adjustment for shared risk factors. When investigating the association between the amount of aortic arch calcification and the risk of cancer, we found only a slightly higher risk, which was not statistically significant. However, when targeting the group of individuals in the highest tertile of calcification, we found 39% increase of the risk of cancer compared to those with the lowest tertile. Further investigation of this association demonstrated that the effect of atherosclerosis on cancer seems to be largest in the short term (during the first 2 years of follow-up). Although this indicates that severe atherosclerosis may be present before cancer diagnosis, it might also reflect reverse causation. It is possible that subclinical cancer development already influences the course of atherosclerosis. Since both atherosclerosis and cancer are conditions with a long preclinical phase, we cannot prove causality, nor can we rule out reverse causation.

Overall, we found no prominent differences in the association between atherosclerosis and cancer before and after adjustment.
TABLE 3 | The association between aortic arch calcification and the risk of cancer while censoring at different time points.

| Aortic arch calcification | n/N | Risk of cancer |
|--------------------------|-----|---------------|
| Per 1-SD increase*       |     | Model I HR (95% CI) | Model II HR (95% CI) |
| Restricted to 2 years of follow-up | 62/2,404 | 1.25 (0.92–1.70) | 1.24 (0.90–1.71) |
| T1 16/802 Ref. | Ref. |
| T2 19/801 1.15 (0.59–2.27) | 1.13 (0.57–2.24) |
| T3 27/801 1.59 (0.80–3.15) | 1.53 (0.75–2.13) |
| Restricted to 3 years of follow-up | 103/2,404 | 1.13 (0.90–1.43) | 1.12 (0.88–1.42) |
| Per 1-SD increase* | 28/802 Ref. | Ref. |
| T1 30/801 1.02 (0.60–1.72) | 1.01 (0.60–1.72) |
| T2 45/801 1.45 (0.86–2.48) | 1.43 (0.83–2.47) |
| Restricted to 4 years of follow-up | 137/2,404 | 1.04 (0.86–1.27) | 1.04 (0.85–1.27) |
| Per 1-SD increase* | 44/802 Ref. | Ref. |
| T1 39/801 0.83 (0.53–1.29) | 0.82 (0.53–1.28) |
| T2 54/801 1.08 (0.69–1.69) | 1.06 (0.67–1.69) |
| T3 183/2,404 | |
| Restricted to 5 years of follow-up | 61/802 Ref. | Ref. |
| Per 1-SD increase* | 51/801 0.80 (0.55–1.17) | 0.81 (0.55–1.18) |
| T1 71/801 1.11 (0.75–1.62) | 1.11 (0.74–1.65) |

TABLE 4 | The association between aortic arch calcification and the risk of different cancer types.

| | n/N | HR per 1-SD increase in aortic arch calcification* |
|--------------------------|-----|--------------------------------------------------|
| | | Model I HR (95% CI) | Model II HR (95% CI) |
| Breast cancer | 45/1,261 | 0.75 (0.55–1.00) | 0.71 (0.52–0.98) |
| Prostate cancer | 72/1,143 | 1.08 (0.82–1.39) | 1.07 (0.81–1.40) |
| Colorectal cancer | 56/2,404 | 1.18 (0.86–1.63) | 1.04 (0.76–1.43) |
| Lung cancer | 40/2,404 | 2.87 (1.72–4.78) | 2.35 (1.39–3.96) |

Sex differences—reflected by differences in hormonal levels—may also influence the apparent different impact of shared risk factors on the development of atherosclerosis and cancer. Aortic arch calcification was associated with a lower risk of breast cancer in women. It has previously been proposed that an inverse association between aortic atherosclerosis and cancer holds in particular for cancers that are hormone-dependent or highly affected by genetics rather than for those caused by exogenous factors (28). Also, aortic arch calcification in particular is strongly associated with mortality, indicating that the inverse relation between aortic arch calcification and cancer may partly be due to residual survival bias (13). More in-depth inquiry on this topic is required.

Several strengths of our study are worth mentioning. Our study is a large prospective population-based study and therefore less vulnerable to selection and information bias than retrospective ones. In addition, we have prospective and unbiased assessment of many risk factors that are not available in healthcare databases. All cancers were pathology proven, which excludes the chance of misclassification. Also, we had an image-based assessment of calcification volumes and standardized ascertainment of cancer incidence.

Yet, some potential limitations need to be addressed. First, despite sufficient power to detect a large effect size of 1.5 for all cancers (α = 0.05, β = 0.80), we acknowledge the lack of statistical power to elaborate on specific cancer types. Second, strong associations of atherosclerosis with the risk of cardiovascular events and mortality may have weakened any potential association of atherosclerosis with cancer. Nevertheless, our finding that the most severe aortic calcification is associated with a higher risk of cancer—while these persons have the highest risk of mortality—might indicate that the effect of survival is limited. Third, the burden of atherosclerosis may influence the prognosis and course of cancer rather than the development itself. Ideally, measures of atherosclerosis at multiple time points are needed to also assess changes in atherosclerotic burden before cancer diagnosis. Future studies...
are needed to unravel differences in the etiology between atherosclerosis and cancer explained by other factors such as genetic and exogenous factors. Lastly, calcification is only a part of the atherosclerotic plaque. Non-calcified parts of the plaques cannot be visualized with non-enhanced CT. Nevertheless, it has been shown that calcification volume is an adequate measure for the total underlying plaque burden (29).

CONCLUSIONS

We found that only individuals with the most severe aortic arch calcification had a higher risk of cancer, potentially through long-term parallel exposure to shared risk factors. Other factors, such as genetic variation or exogenous factors, may further explain susceptibility to either atherosclerosis or cancer.

DATA AVAILABILITY STATEMENT

Data can be obtained upon request. Requests should be made towards the management team of the Rotterdam Study (secretariat.epi@erasmusmc.nl), which has a protocol for approving data requests. Because of restrictions based on privacy regulations and informed consent of the participants, data cannot be made freely available in a public repository.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; www.trialregister.nl) and into the WHO International Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/network/primary/en/) under shared catalog number NTR6831. All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians.

AUTHOR CONTRIBUTIONS

JT, KW, and DB contributed to conception and design of the research. JT, KW, RR, MV, BS, SS, MI, MK, and DB provided essential reagents or provided essential materials. JT and KW analyzed data, performed statistical analysis, and wrote the paper. JT, KW, and DB had primary responsibility for final content. JT, KW, RR, MV, BS, SS, MI, MK, and DB provided intellectual content to the paper. All authors have read and approved the final manuscript.

FUNDING

The Rotterdam Study was funded by Erasmus Medical Center and Erasmus University, Rotterdam; Netherlands Organization for the Health Research and Development (ZonMW); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science; the Ministry for Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. MK was supported by the VENI grant (91616079) from The Netherlands Organization for Health Research and Development (ZonMW). DB was supported by a fellowship of the BrightFocus Foundation (A2017424F) and SS by the Dutch Cancer Society (grant number NKI-20157737). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

ACKNOWLEDGMENTS

We acknowledge the dedication, commitment, and contribution of inhabitants, general practitioners, and pharmacists of the Ommoord district who took part in the Rotterdam Study. We acknowledge Frank van Rooij as data manager and Jolande Verkroost-van Heemst for her contribution to the collection of the data.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.01700/full#supplementary-material

REFERENCES

1. Benjamin Emelia J, Hunsicker P, Alonso A, Bittencourt Marcio S, Callaway Clifton W, Carson April P, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. (2019) 139:e56–28. doi: 10.1161/CIR.0000000000006599
2. Global Burden of Disease Cancer C. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. (2019) 5:1749–68. doi: 10.1001/jamaoncol.2019.2996
3. Whitlock MC, Yeboah J, Burke GL, Chen H, Klepin HD, Hundley WG. Cancer and its association with the development of coronary artery calcification: an assessment from the multi-ethnic study of atherosclerosis. J Am Heart Assoc. (2015) 4:e002533. doi: 10.1161/JAHA.115.002533
4. Hooning MJ, Botma A, Aleman BMP, Baaijens MHA, Bartelink H, Klijn JGM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. (2007) 99:365–75. doi: 10.1093/jnci/djk064
5. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. (2005) 6:401–10. doi: 10.1016/S1470-2045(05)70207-2
6. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. (2007) 25:4370–8. doi: 10.1200/JCO.2006.10.3296
7. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. (2006) 24:4448–56. doi: 10.1200/JCO.2006.06.2497
8. Ross JS, Stagliano NE, Donovan MJ, Breibart RE, Ginsburg GS. Atherosclerosis: a cancer of the blood vessels? *Am J Clin Pathol.* (2001) 116:597–107. doi: 10.1039/YNCK-9R19-3JA3-K2K9

9. Ross JS, Stagliano NE, Donovan MJ, Breibart RE, Ginsburg GS. Atherosclerosis and cancer: common molecular pathways of disease development and progression. *Ann N Y Acad Sci.* (2001) 947:271–92. doi: 10.1111/j.1749-6632.2001.tb03949.x

10. Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and cancer; a resemblance with far-reaching implications. *Arch Med Res.* (2017) 48:12–26. doi: 10.1016/j.arcmed.2017.03.005

11. Kockelkoren R, De Vis JB, de Jong PA, Vernooij MW, Mali WPTM, Hendrikse J, et al. Intracranial carotid artery calcification from infancy to old age. *J Am Coll Cardiol.* (2018) 72:582–4. doi: 10.1016/j.jacc.2018.05.021

12. Thomas IC, Thompson CA, Yang M, Allison MA, Forbang NI, Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and cancer; incidence, risk, and case fatality of first ever stroke in the elderly population. *The Rotterdam study. J Neurol Neurosurg Psychiatry.* (2003) 74:317–21. doi: 10.1136/jnnp.74.3.317

13. Bos D, Leening MJ, Kavousi M, Hofman A, et al. Methods of data collection and definitions of cardiac outcomes in the Rotterdam study. *Eur J Epidemiol.* (2012) 27:173–85. doi: 10.1007/s10654-012-9668-8

14. Ikram MA, Brusselle G, Ghanbari M, Goedegebure A, Ikram MK, Kavousi M, et al. Comparison of atherosclerotic calcification in major vessel beds on the risk of disease-related mortality. *Atherosclerosis Thromb Vasc Biol.* (2018) 38:1926–32. doi: 10.1161/ATVBAHA.118.310850

15. Bos D, van der Lugt A, Hofman A, Hunink MG, Breteler MM, et al. Dietary acid load and risk of hypertension: the Rotterdam study. *Am J Clin Nutr.* (2012) 95:1438–44. doi: 10.3945/ajcn.111.648667

16. Odink AE, van der Lugt A, Hofman A, Hunink MG, Breiter MM, Krestin GP, et al. Association between calcification in the coronary arteries, aortic arch and carotid arteries: the Rotterdam study. *Atherosclerosis.* (2007) 193:408–13. doi: 10.1016/j.atherosclerosis.2006.07.007

17. Bos D, van der Rijk MJ, Geeraertds TE, Hofman A, Krestin GP, Witteman JC, et al. Intracranial carotid artery atherosclerosis: prevalence and risk factors in the general population. *Stroke.* (2012) 43:1878–84. doi: 10.1161/STROKEAHA.112.684667

18. Odink AE, van der Lugt A, Hofman A, Hunink MG, Breiter MM, Krestin GP, et al. Risk factors for coronary, aortic arch and carotid calcification; The Rotterdam Study. *J Hum Hypertens.* (2010) 24:86–92. doi: 10.1038/jhh.2009.42

19. Engberink MF, Bakker SJ, Brink EJ, van Baak MA, van Rooij FI, Hofman A, et al. Dietary acid load and risk of hypertension: the Rotterdam Study. *Am J Clin Nutr.* (2012) 95:1438–44. doi: 10.3945/ajcn.111.022343

20. Diabetes mellitus. *Report of a WHO Study Group.* World Health Organization Technical Report Series (1985), p. 1–113.

21. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam study. *Circulation.* (2004) 109:1089–94. doi: 10.1161/01.CIR.0000120708.59903.1B

22. Hollander M, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, Breteler MM. Incidence, risk, and case fatality of first ever stroke in the elderly population. *The Rotterdam study. J Neurol Neurosurg Psychiatry.* (2003) 74:317–21. doi: 10.1136/jnnp.74.3.317

23. Leening MJ, Kavousi M, Heeringa J, van Rooij FI, Verkroost-van Heemst J, Deckers JW, et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. *J Am Coll Cardiol.* (2018) 72:582–4. doi: 10.1016/j.jacc.2017.03.005

24. Copyright © 2020 van der Toorn, van der Willik, Ruiter, Vernooij, Stricker, Schagen, Ikram, Kavousi and Bos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.